| Literature DB >> 36168574 |
Tolga Can1, Hristo Kirov1, Tulio Caldonazo1, Murat Mukharyamov1, Gloria Färber1, Torsten Doenst1.
Abstract
Mitral valve regurgitation is the second most common valve disease in the western world. Surgery is currently the best tool for generating a long-lasting elimination of mitral valve regurgitation. However, the mitral valve apparatus is a complex anatomical and functional structure, and repair results and durability show substantial heterogeneity. This is not only due to differences in the underlying mitral valve regurgitation pathophysiology but also due to differences in repair techniques. Repair philosophies differ substantially from one surgeon to the other, and consensus for the technically best repair strategy has not been reached yet. We had previously addressed this topic by suggesting that ring sizing is "voodoo". We now review the available evidence regarding the various repair techniques described for structural and functional mitral valve regurgitation. Herein, we illustrate that for structural mitral valve regurgitation, resuspension of prolapsing valve segments or torn chordae with polytetrafluoroethylene sutures and annuloplasty can generate the most durable results paired with the best achievable hemodynamics. For functional mitral valve regurgitation, the evidence suggests that annuloplasty alone is insufficient in most cases to generate durable results, and additional subvalvular strategies are associated with improved durability and possibly improved clinical outcomes. This review addresses current strategies but also implausibilities in mitral valve repair and informs the mitral valve surgeon about the current evidence. We believe that this information may help improve outcomes in mitral valve repair as the heterogeneity of mitral valve regurgitation pathophysiology does not allow a one-size-fits-all concept.Entities:
Keywords: Degenerative mitral regurgitation; functional mitral regurgitation; mitral valve repair
Year: 2022 PMID: 36168574 PMCID: PMC9473589 DOI: 10.5606/tgkdc.dergisi.2022.23340
Source DB: PubMed Journal: Turk Gogus Kalp Damar Cerrahisi Derg ISSN: 1301-5680 Impact factor: 0.704
Figure 1(a) Intraoperative images of the valvular and (b-d) subvalvular units of the mitral valve.
Figure 2(a) Mitral valve repair with leaflet resection and (b) chordal replacement by Schubert et al.[35]
Figure 3(a) Forest plot comparing implanted annuloplasty ring size diameter and (b) mean mitral gradients in mmHg at follow-up after chordal replacement or after leaflet resection techniques. Adapted from Mazine et al.[44]
Summary information for all current trials about resection and nonresection techniques in degenerative MR
| Trial name (follow-up period, year of publication) | Primary end point | Principle of leaflet handling | Number of patients | Early mortality (%) | Freedom from reoperation caused by MR (%) | Freedom from recurrent MR | Survival |
| Chang et al.[ | Early mortality, freedom from cardiac-related deaths, freedom from reoperation, freedom from recurrent MR, reverse LV remodeling | Resect | 363 | 1.4 | 98.2 | 92.7 | 94.2 |
| Flameng et al.[ | Early mortality, Freedom from late cardiac-related deaths, cardiac-related events, freedom from reoperation, NYHA functional class | Resect | 348 | 1.6 | 94.4 | 64.9 | 80.1 |
| Gillinov et al.[ | Early mortality, freedom from late cardiac- related deaths and cardiac-related events, NYHA functional class, and freedom from reoperation | Resect | 1072 | 0.3 | 93 | NA | 81 |
| Çetinkaya et al.[ | Early mortality, recurrent MR, LV ejection fraction, NYHA functional class | Resect r.s . Respect | 363/358 | 1.1/0.4 | NA | 99.6/100 | 88/89.3 |
| Pfannmueller et al.[ | Early mortality, freedom from late cardiac-related deaths freedom from reoperation | Resect r.s . Respect | 383/662 | 1.6/0.7 | 96/97 | NA/NA | 81/85.6 |
| Lazam et al.[ | Early mortality, long-term survival, freedom from recurrent MR, freedom from reoperation, freedom from valve related complications | Respect | 1709 | 1.3 | 95.9 | 88 | 46 |
| Lawrie et al.[ | Early mortality, freedom from recurrent MR, freedom from reoperation | Respect | 662 | 2.6 | 90.1 | 93.9 | NA |
| Shibata et al.[ | Early mortality, long-term survival, freedom from recurrent MR, freedom from reoperation | Respect | 180 | 0.5 | 99.5 | 91.5 | 98.3 |
| Axtell et al.[ | Early mortality, late cardiac-related deaths freedom from recurrent MR, freedom from reoperation, reverse LV remodeling | Respect | 101 | 0 | 100 | 100 | 100 |
| Lawrie et al.[ | Early mortality, long-term survival, freedom from recurrent MR, freedom from reoperation | Respect | 1068 | 1.59 | 96.01 | 94 | 74.65 |
| MR: Mitral regurgitation; LV: Left ventricle; NYHA: New York Heart Association; NA: Not available. | |||||||
Summary information for all current trials about subvalvular mitral repair techniques in functional MR
| Trial name (follow-up period, year of publication) | Study end point | Repair techniques (annuloplasty/annuloplasty + subvalvular techniques) | Number of patients | Early mortality (%) | Freedom from severe MR (%) | Survival (%) |
| Braun et al.[ | Early and late mortality predictors, freedom from recurrent MR, NYHA functional class, reverse LV remodeling | Annuloplasty | 100 | 8 | 98.6 | 71 |
| Acker et al.[ | LV reverse remodeling, mortality, MACCE, recurrent mitral regurgitation, rehospitalization | Annuloplasty | 126 | 1.6 | 95.8 | 84.1 |
| Goldstein et al.[ | LV reverse remodeling, mortality, MACCE, recurrent mitral regurgitation, rehospitalization | Annuloplasty | 126 | NA | 86 | 81 |
| McGee et al.[ | Early and late mortality, predictors of recurrent MR, recurrent MR rates | Annuloplasty | 585 | 6.3 | «30 | 60 |
| Hung et al.[ | LV remodeling, recurrent mitral regurgitation | Annuloplasty | 30 | NA | 24 | NA |
| Harmel et al.[ | Recurrence of MR >2 at the last echocardiographic follow-up (>3 years) LVEF, LVEDD | Annuloplasty vs. annuloplasty + subvalvular techniques | 1093 | NA | 76/90.2 | NA |
| De Varennes et al.[ | Early and late mortality, NYHA functional class, freedom from moderate or severe recurrent MR | Posterior leaflet extension | 44 | 11 | 93 at 3 years | 86 |
| Fattouch et al.[ | Early mortality, Freedom from late cardiac-related deaths, cardiac-related events, NYHA functional class, reverse LV remodeling | Papillary muscle relocation | 55 | 3.6 | 96.4 | 91 |
| Fattouch et al.[ | Early mortality, freedom from cardiac-related deaths and events, freedom from recurrent MR, NYHA functional class, reverse LV remodeling | Papillary muscle relocation | 115 | 3.4 | 97.3 | 90.9 |
| Fattouch et al.[ | Early mortality, freedom from late cardiac-related deaths and cardiac-related events, and reverse LV remodeling | Papillary muscle relocation | 69 | 4.3 | 97.2 | NA |
| Roshanali et al.[ | Early mortality, freedom from recurrent MR, NYHA functional class | Papillary muscle approximation | 100 | 6.5 | 96.6 | NA |
| Nappi et al.[ | Early mortality, freedom from late cardiac-related deaths and cardiac-related events, and reverse LV remodeling | Papillary muscle approximation | 48 | 4.2 | 73 | 77.1 |
| Wakasa et al.[ | Early mortality, late cardiac-related deaths freedom from recurrent MR, NYHA functional class | Papillary muscle approximation | 26 | 12 | 4.4 vs. 3.7 | 89 |
| Trial name (follow-up period, year of publication) | Study end point | Repair techniques (annuloplasty/annuloplasty + subvalvular techniques) | Number of patients | Early mortality (%) | Freedom from severe MR (%) | Survival (%) |
| Hvass and Joudinaud[ | Early mortality, late cardiac-related deaths, NYHA functional class | Papillary muscle approximation (sling) | 37 | 5.4 | NA | 80 |
| Nappi et al.[ | Early mortality, freedom from late cardiac-related deaths and cardiac-related events, and reverse LV remodeling | Papillary muscle approximation | 48 | 4.2 | 73 | 83.3 |
| Langer et al.[ | Early mortality, late cardiac-related deaths freedom from recurrent MR | Ring + String | 30 | 6.6 | 96 | 89 |
| Pingpoh et al.[ | Early mortality | Ring-Noose-String | 10 | 0 | NA | NA |
| Borger et al.[ | Early mortality, late cardiac-related deaths and cardiac-related event, freedom from recurrent MR | Secondary chorda cutting | 43 | 9 | 85 | 79 |
| Murashita et al.[ | Early mortality, late cardiac-related deaths and cardiac-related event, freedom from recurrent MR, NYHA functional class, reverse LV remodeling | Secondary chorda cutting | 15 | 0 | 80 | 80.8 |
| de Varennes et al.[ | Early mortality, late cardiac-related deaths and cardiac-related event, freedom from recurrent MR, NYHA functional class, reverse LV remodeling | Patch enlargement | 44 | 11 | 90 | 73 |
| MR: Mitral regurgitation; NYHA: New York Heart Association; LV: Left ventricle; MACCE: Major adverse cardiac and cerebrovascular events; LVEF: Left ventricle ejection fraction; LVEDD: Left ventricle end diastolic diameter; NA: Not available. | ||||||
Figure 4(a) Illustration of papillary muscle displacement by functional MR, and surgical strategies addressing the subvalvular apparatus; (b) relocation of the posterior papillary muscle;[74] (c) schematic illustrations depicting three-dimensional anterior and posterior papillary muscles displacement vectors in experimental ovine models of ischemic MR and functional MR;[86] (d) Ring and String technique;[76] (e) Girdauskas technique;[91] (f) Ring-Noose-String technique.[19] MR: Mitral regurgitation; LA: Left atrium; LV: Left ventricle; APM: Anterior papillary muscle; PPM: Posterior papillary muscle; FMR: Functional mitral regurgitation.